Has Mark Robson, DPM received payments from drug or device companies?

Yes. Drug and device makers reported $3,901 in general payments to Mark Robson, DPM across 124 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Mark Robson, DPM did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Mark Robson, DPM come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Mark Robson, DPM

Foot & Ankle Surgery · Austin, TXNPI 1861467904

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $3,435 of the $3,901 with a category attached, or 88.0%. 27 manufacturers reported payments, led by Stryker at 54.3% of the total. That places this record below the midpoint for foot & ankle surgery clinicians in TX, where the typical reported total is $3,901.

$3,901in general payments, 2019–2025

Across 124 payments — averaging $31.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Stryker$2K
AbbVie$400
Treace Medical Concepts, Inc.$194
Amgen$124
Abbott$121
Anika Therapeutics, Inc.$101
plus $844 from 21 others

$953,534in research payments, 2019–2025

Across 2 payments — averaging $476,767 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Vertex$954K

What the payments were for

Travel & lodging$46612%
Food & beverage$3,43588%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Stryker	40	$2,117
AbbVie	17	$400
Treace Medical Concepts, Inc.	9	$194
Amgen(2 entities)	6	$124
Abbott	7	$121
Anika Therapeutics, Inc.	4	$101
Paratek Pharmaceuticals, Inc.	4	$67
Ossio Inc	1	$67
Convatec Inc.	3	$62
Johnson & Johnson	2	$57
Orthofix Medical, Inc.	7	$57
Medtronic	2	$56
Kerecis Limited	2	$53
Nevro Corp.	2	$45
GRT US Holding, Inc.	2	$44
Smith+Nephew	2	$44
ERMI LLC	2	$39
Triad Life Sciences Inc.	2	$35
Integra Lifesciences Corporation	2	$34
Bone Support Inc.	1	$32
Mimedx Group, Inc.	1	$31
Reddress USA, Inc.	1	$26
Organogenesis Inc.	1	$24
Heron Therapeutics, Inc.	1	$22
Acera Surgical, Inc.	1	$18
Tactile Systems Technology Inc	1	$17
Davol Inc.	1	$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,901 in reported general payments places this provider in the 50th percentile of 684 foot & ankle surgery providers in Texas.

See all foot & ankle surgery providers in Texas →

Medicare billing

Part B allowed, 2024

$159,577

Medicare patients

399

Services billed

1,522

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Terbinafine Hcl	61	$389
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav	32	$272
Ketoconazole	14	$204
Ammonium Lactate	12	$200
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim	19	$117
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen	15	$115
Methylprednisolone	14	$113
Cephalexin	23	$112
Azithromycin	14	$72

Paid to pharmacies, not to this prescriber.

Other foot & ankle surgery in Austin

Mark DaltonAustin$1.9M
Andrew EbertAustin$82K
Pedro CosculluelaAustin$69K
William McGarveyKaty$3.5M
Eugene CurryDallas$3.1M
Graham HamiltonEdinburg$2.1M
Kevin VarnerHouston$1.1M
Paul KimDallas$928K
Sherman NaglerHouston$602K
John EarlyDallas$553K

See the full list for Texas →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →